Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical and Therapeutic Impact of Molecular Markers in Myeloproliferative Neoplasms (CTIM3)

NCT02823210 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.

NCT NCT02823210
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02823210 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical and Therapeutic Impact of Molecular Markers in Myeloproliferative Neoplasms (CTIM3)
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Observational
Overall status
Unknown status
Start date
June 30, 2016
Completion date
June 30, 2019
Enrollment
300 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

myeloproliferative neoplasms